Skip to main content
CDC Website

Viral Hepatitis

Opportunity to Strengthen Access to Hepatitis C Treatment Through Section 1115 Justice-Involved Reentry Initiative Demonstrations

This report lays out the required sections that must be included in a state’s Section 1115 Demonstration application and identifies where and how a state can be explicit about its intent to address the health care needs of individuals with hepatitis C as part of its Justice-Involved Reentry Initiative.

What You Need to Know About the New Hepatitis C Test

This article highlights a new hepatitis C test that delivers rapid results without requiring a separate lab visit, improving access to early diagnosis and treatment. It emphasizes the importance of expanding testing efforts, particularly for high-risk populations, to support hepatitis C elimination. The article underscores the need for continued innovation in screening technologies to reduce barriers to care and prevent long-term health complications like liver disease and cancer.

Simplifying Hepatitis B

This video highlights the rules about who to screen and vaccinate for hepatitis B and how they are now more clinician-friendly.

Substance Use Disorder and the Hep C Connection

In this episode of Beyond Substance podcast, Jason Rush shares his journey through addiction and hepatitis C, while Dr. Janet Arno provides expert insight on treatment and public health solutions.

Current Methadone Access: Where are we now?

NASTAD, in partnership with the National Coalition to Liberate Methadone (NCLM) held the “Part 2: Part 2: Current Methadone Access: Where are we now?” webinar on September 24 . Methadone is an essential tool for saving lives during an overdose crisis and reducing the risk of HIV and hepatitis C transmission among people who inject drugs. NCLM advocates for a more accessible and equitable methadone system that prioritizes patient health, promotes dignity, and is grounded in evidence.

History of the Methadone System: How did we get here?

NASTAD, in partnership with the National Coalition to Liberate Methadone (NCLM) held the “Part 1: History of the Methadone System: How did we get here?” webinar on September 11 . Methadone is an essential tool for saving lives during an overdose crisis and reducing the risk of HIV and hepatitis C transmission among people who inject drugs. NCLM advocates for a more accessible and equitable methadone system that prioritizes patient health, promotes dignity, and is grounded in evidence.

History of the Methadone System: How did we get here?

NASTAD, in partnership with the National Coalition to Liberate Methadone (NCLM) held the “Part 1: History of the Methadone System: How did we get here?” webinar on September 11 . Methadone is an essential tool for saving lives during an overdose crisis and reducing the risk of HIV and hepatitis C transmission among people who inject drugs. NCLM advocates for a more accessible and equitable methadone system that prioritizes patient health, promotes dignity, and is grounded in evidence.

Estimating hepatitis C prevalence in the United States, 2017–2020

The National Health and Nutrition Examination Survey (NHANES) underestimates the true prevalence of hepatitis C virus (HCV) infection in the U.S. due to inadequate representation of certain populations. Two models were developed to provide more accurate estimates of HCV prevalence among U.S. adults from 2017 to 2020.

Was this page helpful? Give Feedback